Skip to content
Clinical Trials – home
CzechiaBack to Czechia

Clinical trials in Usti Nad Labem – page 48

1 086 clinical trials in Usti Nad Labem, Czechia across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Usti Nad Labem at a glance
1 086
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

1 086 trials in Usti Nad Labem

Open in trial search

Hypertriglyceridaemia

Not recruiting

Study of Plozasiran for Adults with Severe Hypertriglyceridemia

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Colitis ulcerative+1

Not recruiting

Study on the Long-Term Effects of TEV-48574 (Duvakitug) for Adults with Moderate to Severe Ulcerative Colitis or Crohn's Disease

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Teva Branded Pharmaceutical Products R&D LLC

Systemic scleroderma

Not recruiting

Study on the Effects of Fipaxalparant in Patients with Diffuse Cutaneous Systemic Sclerosis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Fipaxalparant
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Hot flush

Not recruiting

Study of Fezolinetant for Hot Flashes in Women with Hormone Receptor-Positive Breast Cancer Receiving Hormone Therapy

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Fezolinetant
  • Sponsor:Astellas Pharma Global Development Inc.

Ovarian cancer

Not recruiting

Study on the Effectiveness of Durvalumab, Olaparib, and Bevacizumab in Patients with Newly Diagnosed Advanced Ovarian Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AstraZeneca AB

Hypertriglyceridaemia

Not recruiting

Study to Evaluate Plozasiran for Adults with High Triglycerides

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Migraine

Not recruiting

Study on the Safety and Effectiveness of MEDI0618 for Reducing Migraine Days in Adults with Episodic Migraine

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:MEDI0618
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Barzolvolimab for Patients with Chronic Spontaneous Urticaria Unresponsive to H1 Antihistamines

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Gastric cancer+1

Not recruiting

Study on Durvalumab and FLOT Chemotherapy for Patients with Resectable Gastric and Gastroesophageal Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:AstraZeneca AB

Conjunctivitis allergic+1

Not recruiting

Study on Mannan-Conjugated Birch Pollen Allergoids for Adolescents and Adults with Birch Pollen-Induced Allergic Rhinitis or Rhinoconjunctivitis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Betula Pendula Pollen Allergoid, Mannan-Conjugated, Polymerised
  • Sponsor:CCDRD Cooperative Clinical Drug Research and Development AG

Study Comparing DB-1303 and Chemotherapy for Patients with HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Dualitybio Inc.

Study on Long-term Safety of TAK-881 (Human Normal Immunoglobulin, Hyaluronidase) for Patients with Primary Immunodeficiency Diseases

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:Baxalta Innovations GmbH

Other cities in Czechia

The busiest research cities in the country

All 150 cities in Czechia

Clinical research in Usti Nad Labem

What the registry says about research in the country

01 Cardiovascular Research

Innovative trials focusing on cardiovascular disease management and prevention, including studies on hypertrophic cardiomyopathy and treatments for acute myocardial infarction.

  • Heart failure treatments
  • Stroke prevention
  • Deep vein thrombosis therapy

Several studies are evaluating novel compounds to reduce cardiovascular events and improve patient outcomes.

02 Gastrointestinal Studies

Multiple clinical investigations targeting Crohn's Disease, with research focusing on innovative therapies and treatment combinations for moderate to severe cases.

  • Inflammatory bowel disease management
  • Novel therapeutic approaches
  • Long-term disease control

Research aims to improve quality of life for patients with chronic gastrointestinal conditions.

03 Metabolic Disorders

Comprehensive research into diabetes management and hypertriglyceridemia, including specialized treatments for both Type 1 and Type 2 diabetes in various age groups.

  • Blood sugar control
  • Lipid management
  • Pediatric diabetes care

Studies focus on developing targeted therapies for better metabolic control.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.